These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Vaccinomics: a future avenue for vaccine development against emerging pathogens. de la Fuente J; Contreras M Expert Rev Vaccines; 2021 Dec; 20(12):1561-1569. PubMed ID: 34582295 [TBL] [Abstract][Full Text] [Related]
23. Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases. Feng F; Wen Z; Chen J; Yuan Y; Wang C; Sun C Viruses; 2022 Mar; 14(3):. PubMed ID: 35336927 [TBL] [Abstract][Full Text] [Related]
25. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703 [TBL] [Abstract][Full Text] [Related]
26. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice. Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398 [TBL] [Abstract][Full Text] [Related]
27. Antigen delivery by dendritic cells. Moll H Int J Med Microbiol; 2004 Oct; 294(5):337-44. PubMed ID: 15532992 [TBL] [Abstract][Full Text] [Related]
28. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice. Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603 [TBL] [Abstract][Full Text] [Related]
29. Vaccine development for emerging infectious diseases. Excler JL; Saville M; Berkley S; Kim JH Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611 [TBL] [Abstract][Full Text] [Related]
30. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Kang TH; Lee JH; Noh KH; Han HD; Shin BC; Choi EY; Peng S; Hung CF; Wu TC; Kim TW Int J Cancer; 2007 Apr; 120(8):1696-703. PubMed ID: 17230516 [TBL] [Abstract][Full Text] [Related]
31. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo. Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535 [TBL] [Abstract][Full Text] [Related]
32. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088 [TBL] [Abstract][Full Text] [Related]
33. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines. Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788 [TBL] [Abstract][Full Text] [Related]
34. Targeting Velasquez LN; Stüve P; Gentilini MV; Swallow M; Bartel J; Lycke NY; Barkan D; Martina M; Lujan HD; Kalay H; van Kooyk Y; Sparwasser TD; Berod L Front Immunol; 2018; 9():471. PubMed ID: 29662482 [TBL] [Abstract][Full Text] [Related]
35. Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo. Wang P; Dong S; Zhao P; He X; Chen M Biomaterials; 2018 Nov; 182():92-103. PubMed ID: 30107273 [TBL] [Abstract][Full Text] [Related]
36. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727 [TBL] [Abstract][Full Text] [Related]
37. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751 [TBL] [Abstract][Full Text] [Related]
38. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Lapteva N; Seethammagari MR; Hanks BA; Jiang J; Levitt JM; Slawin KM; Spencer DM Cancer Res; 2007 Nov; 67(21):10528-37. PubMed ID: 17974997 [TBL] [Abstract][Full Text] [Related]
39. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502 [TBL] [Abstract][Full Text] [Related]
40. [Dendritic cells of mucosa and skin: "recruited for vaccination"]. Le Borgne M; Dubois B; Kaiserlian D Med Sci (Paris); 2007 Oct; 23(10):819-25. PubMed ID: 17937889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]